Department of Medical Oncology, Dana-Farber Cancer Institute, and.
Harvard Medical School, Boston, Massachusetts.
J Natl Compr Canc Netw. 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554.
Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast cancer (TNBC), which has several key characteristics that enhance ICI responses. Strategies to improve anticancer immune responses in TNBC are urgently needed to extend survival for patients with metastatic disease. This review presents ICI monotherapy response rates and discusses combination strategies with chemotherapy, targeted therapies, and novel immunotherapies. It concludes with a summary of immunotherapy biomarkers in TNBC and a call to action for future directions of research critical to advancing the efficacy of immunotherapy for patients with TNBC.
免疫检查点抑制剂 (ICIs) 已在许多转移性癌症中导致持久的临床缓解。然而，ICI 在乳腺癌中的单一药物疗效较低，包括三阴性乳腺癌 (TNBC)，其具有增强 ICI 反应的几个关键特征。迫切需要改善 TNBC 中的抗癌免疫反应的策略，以延长转移性疾病患者的生存时间。本综述介绍了 ICI 单药治疗的缓解率，并讨论了与化疗、靶向治疗和新型免疫疗法的联合策略。最后总结了 TNBC 中的免疫治疗生物标志物，并呼吁为推进 TNBC 患者免疫治疗的疗效的未来研究方向采取行动。
